Tris-CAR-T is under clinical development by Tasly Pharmaceutical Group and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tris-CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tris-CAR-T overview
Tasly Pharmaceutical Group overview
Tasly Pharmaceutical Group (Tasly) manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food and other products. The company’s product line includes herbal medicine, chemical medicine, prescription drugs, pharmaceutical substances, health product, active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series, and medical equipment. It markets products in the domestic market through its own sales force and through distributors and subsidiaries in Malaysia, Indonesia, Vietnam, South Korea, Pakistan, Thailand, Istanbul, Botswana, South Africa, Ghana, Kenya, Zambia, Nigeria, Russia, the Netherlands, and the US. Tasly is headquartered in Tianjin, China.
For a complete picture of Tris-CAR-T’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.